PUNE, India, April 23, 2024 /PRNewswire/ -- The report
titled "Glycated Albumin Assay Market by Product
(Animal Glycated Albumin Assay, Human Glycated Albumin Assay),
Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End
User - Global Forecast 2024-2030" is now available on
360iResearch.com's offering, presents an analysis indicating that
the market projected to grow from a size of $217.29 million in 2023 to reach $360.92 million by 2030, at a CAGR of 7.51% over
the forecast period.
"The Global Rise of Glycated Albumin
Assays"
The glycated albumin assay, an innovative diagnostic tool, is
gaining importance worldwide for its ability to accurately measure
glycated albumin levels in the blood, providing an essential
alternative for diabetes management, especially for individuals
facing inaccuracies with traditional HbA1c tests due to conditions
such as hemoglobinopathies, recent blood transfusions, or chronic
kidney or liver diseases. This test is essential in modifying
diabetes treatment plans swiftly, aiming for improved short-term
blood glucose regulation. With diabetes prevalence on the rise and
a growing emphasis on vigilant monitoring and control of blood
glucose levels, the need for precise and dependable testing methods
such as the glycated albumin assay is more urgent than ever.
Challenges include variations in reimbursement policies and
regulatory landscapes across different countries and the expanding
healthcare infrastructure in emerging markets. Ongoing research
into new glucose regulation biomarkers is set to propel the growth
of the glycated albumin assay market. In the Americas, the demand
is driven by a high prevalence of diabetes and well-established
healthcare systems. In Europe, the
approach is focused on early disease detection among its aging
population, and the Asia-Pacific
market is expanding rapidly owing to increasing diabetes awareness
and technological advancements; the adoption of glycated albumin
assays is becoming more widespread. Furthermore, the rise in
lifestyle-related diseases has spurred initiatives to adopt such
state-of-the-art diagnostic techniques in the Middle East and Africa, underscoring a global movement toward
better diabetes management and control.
Download Sample Report
@ https://www.360iresearch.com/library/intelligence/glycated-albumin-assay
"Global Initiatives Enhance Early Diabetes
Detection through Advanced Screening Programs"
Governments around the world are implementing efforts to combat
the rising tide of diabetes by launching comprehensive screening
initiatives aimed at early detection, which is essential in
management of the disease and prevention of severe complications.
In the United States, the National
Diabetes Prevention Program, supported by the Centers for Disease
Control and Prevention (CDC), is at the forefront, promoting
regular screenings for prediabetes and Type 2 diabetes, essential
steps in curbing the disease's progression. Across the Atlantic,
the UK's EarLy Surveillance for Autoimmune Diabetes (ELSA) project
is pioneering early detection and management of type 1 diabetes
among children. Central to these efforts is the inclusion of the
glycated albumin assay, a key diagnostic tool recommended by health
authorities in Europe and
Asia for those at risk or already
diagnosed with diabetes. These governmental health initiatives
underscore a global commitment to integrating cutting-edge
technologies, like the glycated albumin assay, in the fight against
diabetes, emphasizing the importance of early detection in
safeguarding public health.
"Glycated Albumin Assay Is A Key to Early
Diabetes Management and Insightful Lifestyle
Adjustments"
In diabetes management and prevention, the glycated albumin
assay emerges as a pivotal tool, especially for those at the
precipice of diabetes, known as prediabetics. Prediabetes, a
condition marked by slightly elevated blood glucose levels, however
not high enough to diagnose diabetes, can often be a wake-up call.
The glycated albumin assay is valuable, offering short-term
fluctuations in blood glucose that could guide timely interventions
to prevent the development of Type 2 diabetes. This assay is
essential for prediabetics, allowing them to witness the immediate
effects of lifestyle adjustments, such as exercise and diet
modifications, on their blood sugar levels. Moreover, for
individuals battling Type 1 diabetes, where the immune system
attacks cells producing insulin, glycated albumin assays serve as a
crucial adjunct to the long-standing Hemoglobin A1c test, offering
faster, more current insights into glucose levels and thereby
aiding in fine-tuning treatment plans. Its application in managing
Type 2 diabetes is exceptional. Providing an average of blood
glucose over a shorter span of about two to four weeks than
traditional markers empowers individuals with Type 2 diabetes to
swiftly gauge the impact of changes in their lifestyle or
medication, ensuring more effective management of the
condition.
Request Analyst Support
@ https://www.360iresearch.com/library/intelligence/glycated-albumin-assay
"Asahi Kasei Corporation at the Forefront
of Glycated Albumin Assay Market with a Strong 22.09% Market
Share"
The key players in the Glycated Albumin Assay Market include
Laboratory Corporation of America Holdings, EKF Diagnostics
Holdings by IBL PLC, Asahi Kasei Corporation, Thermo Fisher
Scientific Inc., Cardinal Health, Inc., and others. These prominent
players focus on strategies such as expansions, acquisitions, joint
ventures, and developing new products to strengthen their market
positions.
"Introducing ThinkMi: Revolutionizing
Market Intelligence with AI-Powered Insights for the Glycated
Albumin Assay Market"
We proudly unveil ThinkMi, a cutting-edge AI product designed to
transform how businesses interact with the Glycated Albumin Assay
Market. ThinkMi stands out as your premier market intelligence
partner, delivering unparalleled insights with the power of
artificial intelligence. Whether deciphering market trends or
offering actionable intelligence, ThinkMi is engineered to provide
precise, relevant answers to your most critical business questions.
This revolutionary tool is more than just an information source;
it's a strategic asset that empowers your decision-making with
up-to-the-minute data, ensuring you stay ahead in the fiercely
competitive Glycated Albumin Assay Market. Embrace the future of
market analysis with ThinkMi, where informed decisions lead to
remarkable growth.
Ask Question to ThinkMi
@ https://app.360iresearch.com/library/intelligence/glycated-albumin-assay
"Dive into the Glycated Albumin Assay
Market Landscape: Explore 184 Pages of Insights, 284 Tables, and 22
Figures"
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Glycated Albumin Assay Market, by Product
- Glycated Albumin Assay Market, by Application
- Glycated Albumin Assay Market, by End User
- Americas Glycated Albumin Assay Market
- Asia-Pacific Glycated Albumin Assay Market
- Europe, Middle East & Africa Glycated Albumin
Assay Market
- Competitive Landscape
- Competitive Portfolio
Inquire Before Buying
@ https://www.360iresearch.com/library/intelligence/glycated-albumin-assay
Related Reports:
- Type 2 Diabetes Drugs Market - Global Forecast 2024-2030
- Diabetes Diagnostics Market - Global Forecast 2024-2030
- Diabetes Drugs Market - Global Forecast 2024-2030
About 360iResearch
Founded in 2017, 360iResearch is a market research and business
consulting company headquartered in India, with clients and focus markets spanning
the globe.
We are a dynamic, nimble company that believes in carving
ambitious, purposeful goals and achieving them with the backing of
our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes
to market intelligence and volatility. Our market intelligence is
diligent, real-time and tailored to your needs, and arms you with
all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500,
and leading consulting and research companies and academic
institutions that rely on our expertise in compiling data in niche
markets. Our meta-insights are intelligent, impactful and infinite,
and translate into actionable data that support your quest for
enhanced profitability, tapping into niche markets, and exploring
new revenue opportunities.
Contact 360iResearch
Mr. Ketan Rohom
360iResearch Private Limited,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
Email: sales@360iresearch.com
USA: +1-530-264-8485
India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn,
Twitter, and Facebook.
Logo:
https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/glycated-albumin-assay-market-projected-to-reach-360-92-million-by-2030---exclusive-report-by-360iresearch-302124130.html